BFM
VKTX icon

Boothbay Fund Management’s Viking Therapeutics VKTX Stock Holding History

Boothbay Fund Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-60,000
Closed -$3.18M – 1960
2024
Q2 		$3.18M Buy
60,000
+6,600
+12% +$433K 0.08% 348
2024
Q1 		$4.38M Buy
+53,400
New +$2.38M 0.08% 266
2020
Q1 		– Sell
-281
Closed -$225K – 1073
2019
Q4 		$225K Buy
+281
New +$2.05K 0.02% 675

Other funds holding VKTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Boothbay Fund Management's VKTX Position: Q4 2025 in Review

Boothbay Fund Management sold out of Viking Therapeutics (VKTX) in Q4 2025, closing a stake of 11,205 shares — an estimated $294K sold.

Boothbay Fund Management first reported a position in VKTX in Q4 2017 and held it in 18 quarters. The position peaked at $3.28M in Q2 2024. 424 funds tracked by Wall St. Rank hold VKTX as of Q4 2025.

  • Boothbay Fund Management reported no remaining Viking Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Boothbay Fund Management sold 11,205 Viking Therapeutics shares in Q4 2025, an estimated $294K.
  • Boothbay Fund Management first reported a position in Viking Therapeutics in Q4 2017 and held it in 18 quarters.
  • Boothbay Fund Management's Viking Therapeutics position peaked at $3.28M in Q2 2024.
  • 424 funds tracked by Wall St. Rank held Viking Therapeutics as of Q4 2025.

Based on Boothbay Fund Management's 13F filing for Q4 2025, filed 17 Feb 2026.